Compare Mesoblast Limited (MESO) vs Roblox Corp (RBLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Roblox Corp — how do they compare? Mesoblast Limited trades at $16.79 (market cap $2.21B), while Roblox Corp trades at $35.76 (market cap $25.87B). The key difference: Roblox Corp is far larger — about 11.7× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals.
| MESO | RBLX | |
|---|---|---|
Market Cap | $2.21B | $25.87B |
Sector | Technology | Media |
52-Week High | $20.96 | $141.56 |
52-Week Low | $12.88 | $35.60 |
Enterprise Value | $2.21B | $24.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
Roblox (RBLX) trades at $35.33, down 4.64% on the day, amid a bearish technical signal and negative investor sentiment driven by multiple class-action lawsuits. The company shows strong revenue growth, with 2025 revenue reaching $4.89 billion, but remains unprofitable with a net income margin of -17.61%. Recent earnings have beaten expectations, yet management withdrew full-year 2026 guidance, increasing uncertainty.
The outlook is mixed: robust user engagement and revenue growth offer long-term potential, but near-term risks from legal challenges and persistent losses warrant caution. Analyst consensus is a Buy with a $45.67 price target, suggesting upside if execution improves, though volatility from negative news flow may pressure the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
